Cystathionine-gamma-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas.

  • NORLUX Neuro-Oncology Laboratory
  • Proteomics of Cellular Signaling
  • Quantitative Biology Unit
  • Cancer Metabolism Group
April 09, 2021 By:
  • Cano-Galiano A
  • Oudin A
  • Fack F
  • Allega MF
  • Sumpton D
  • Martinez-Garcia E
  • Dittmar G
  • Hau AC
  • De Falco A
  • Herold-Mende C
  • Bjerkvig R
  • Meiser J
  • Tardito S
  • Niclou SP.

Background: Mutations in isocitrate dehydrogenase 1 or 2 (IDH1/2) define glioma subtypes and are considered primary events in gliomagenesis, impacting tumor epigenetics and metabolism. IDH enzyme activity is crucial for the generation of reducing potential in normal cells, yet the impact of the mutation on the cellular antioxidant system in glioma is not understood. The aim of this study was to determine how glutathione (GSH), the main antioxidant in the brain, is maintained in IDH1-mutant gliomas, despite an altered NADPH/NADP balance. Methods: Proteomics, metabolomics, metabolic tracer studies, genetic silencing, and drug targeting approaches in vitro and in vivo were applied. Analyses were done in clinical specimen of different glioma subtypes, in glioma patient-derived cell lines carrying the endogenous IDH1 mutation and corresponding orthotopic xenografts in mice. Results: We find that cystathionine-gamma-lyase (CSE), the enzyme responsible for cysteine production upstream of GSH biosynthesis, is specifically upregulated in IDH1-mutant astrocytomas. CSE inhibition sensitized these cells to cysteine depletion, an effect not observed in IDH1 wild-type gliomas. This correlated with an increase in reactive oxygen species and reduced GSH synthesis. Propargylglycine (PAG), a brain-penetrant drug specifically targeting CSE, led to delayed tumor growth in mice. Conclusions: We show that IDH1-mutant astrocytic gliomas critically rely on NADPH-independent de novo GSH synthesis via CSE to maintain the antioxidant defense, which highlights a novel metabolic vulnerability that may be therapeutically exploited.

2021 Apr. Neurooncol Adv.3(1):vdab057.
Other information